GRFS Key Stats
| Income Statement | |
| Revenue TTM | 3.391B |
| Revenue Quarterly YoY Growth | -1.28% |
| EPS Diluted TTM | 1.066 |
| EPS Diluted Quarterly YoY Growth | 29.95% |
| Net Income TTM | 356.05M |
| Profitability | |
| Gross Profit Margin Quarterly | 51.19% |
| Profit Margin Quarterly | 12.88% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 14.93B |
| Enterprise Value | 18.11B |
| PE Ratio TTM | 25.21 |
| PE 10 Pro | Go Pro |
| PEG Ratio | 0.0866 |
| Price / Book Value | 5.959 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 1.444 |
| Free Cash Flow | 76.82M |
| Return on Equity | 14.96% |
GRFS News
- Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Ag... 7:00 AM
- Stocks Mostly Higher In Late Trade; Actavis Jumps May 10
- Stocks Mixed In Early Afternoon; Priceline, Nvidia Up May 10
- Europe Emerges As Leader Of Foreign Stocks' Q1 Earnings May 9
- Stocks Stay On Track, Log More Gains May 7
- Stocks Rise With Dow, S&P Headed For New Record Highs May 7
- 4 Stocks Pushing The Drugs Industry Downward May 7
- Stocks Mixed As Nasdaq Wobbles: EOG Resources Bolts Higher May 7
- Stocks Mixed In Afternoon; Qihoo, Alaska Air Jump May 6
- Acquisitions, Global Thinking Boost Spanish Biotech Grifols May 2
GRFS Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Grifols is up 60.24% over the last year vs S&P 500 Total Return up 31.97%, Cadence Pharmaceuticals up 139.0%, and ARCA biopharma down 5.73%.
GRFS Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these GRFS related companies
Pro Ratings for GRFS
Pro Report PDF for GRFS
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download GRFS Pro Report PDF
Pro Strategies Featuring GRFS
Did Grifols make it into our Pro Portfolio Strategies?
GRFS Profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Other GRFS Resources
- Company Website
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| GRFS | 26.86 | -0.14 | -0.52% | 14.93B |
